KalVista Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

KalVista Pharmaceuticals şirketinin toplam hissedar öz sermayesi $172.8M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $200.2M ve $27.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$174.27m
Eşitlik	US$172.80m
Toplam yükümlülükler	US$27.40m
Toplam varlıklar	US$200.20m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4XC1 'nin kısa vadeli varlıkları ( $191.6M ) kısa vadeli yükümlülüklerini ( $22.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4XC1 şirketinin kısa vadeli varlıkları ( $191.6M ) uzun vadeli yükümlülüklerini ( $5.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4XC1 borçsuzdur.

Borcun Azaltılması: 4XC1 son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4XC1 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 4XC1 serbest nakit akışı her yıl % 25.9 1 yıl yetecek nakit akışına sahip olacaktır.

KalVista Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc.

Forecast to breakeven in 2027

KalVista Pharmaceuticals, Inc. Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

New major risk - Share price stability

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

New major risk - Financial position

Kalvista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 03, 2024

KalVista Pharmaceuticals, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

No longer forecast to breakeven

New minor risk - Profitability

KalVista Pharmaceuticals, Inc. Initiates KONFident-KID Trial for On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology (Eaaci) Congress 2024

Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

Forecast to breakeven in 2027

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

CEO & Director recently sold €817k worth of stock

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema

New minor risk - Profitability

New major risk - Financial position

Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development

Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Announces Management Changes

KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

No longer forecast to breakeven

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief from HAE Attacks in Patients

KalVista Pharmaceuticals, Inc. to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022

U.S. Food and Drug Administration Lifts the Clinical Hold on Kalvista Pharmaceuticals, Inc.’s Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 3000E Value Index

KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Appoints Nancy Stuart to Board of Directors and Audit Committee

Revenue misses expectations

KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

New 90-day low: €12.50

Kalvista Pharmaceuticals, Inc. Provides Data on Kvd824 as Twice-Daily Oral Candidate for Prophylactic Treatment of Hae; Announces Novel Oral Factor Xiia Inhibitor Program as the Next Area of Development Focus

Revenue misses expectations

Kalvista Pharmaceuticals, Inc. Reports Demise of Arnold Oronsky on November 21, 2020

New 90-day high: €16.20

KalVista Pharmaceuticals, Inc. Announces Updated Guidance on the Data Release of Its Phase 2 Clinical Trial

New 90-day high: €14.60

KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

New 90-day high: €11.90

New 90-day high - €11.60

First quarter earnings released

New 90-day high - €11.50

New 90-day low - €8.55

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin